Camptothecin (CPT) is a cytotoxic quinoline alkaloid which inhibits the DNA enzyme Topoisomerase-I (Topo-I) and has shown remarkable anticancer activity in preliminary clinical trials. The major limitation is its low solubility and high adverse reaction. In the studied work, we performed molecular docking of CPT derivatives against Topo-I and developed the quantitative structure activity relationship (QSAR) model for anticancer activity screening. For QSAR, we used CPT and other anticancer drugs with its IC 50 values. We used a total of forty seven anticancer drugs as training set and eight compounds as test set and thirty derivatives of CPT as query set. Total of fifty two chemical descriptors were used for the quantitative data calculation. Only four showed good correlation with the experimental activity. Forward feed regression method was used for development of multiple linear regression (MLR) QSAR model. Model showed acceptable regression coefficient (r 2 ) 0.89 (i.e., 89% of correlation) and cross validation coefficient (rCV 2 ) 0.86 (i.e., 86 % of prediction accuracy). After drug likeness test, ten compounds namely, MSB3a, MSB3b, MSB19, MSB22L, MSB22M, MSB22O, MSB22R, MSB25D, MSB37G and MSB39D, showed promising predicted anticancer activity and drug likeness properties. Out of ten, only six compounds namely, MSB19, MSB22L, MSBM, MSB22O, MSB22R and MSB37D indicate two times more activity than the parent CPT compound. In molecular docking studies, all the identified active CPT derivatives showed high binding affinity with Topo-I. QSAR study indicates that connectivity index, electron affinity, mol.wt. & ether group count highly contribute to inhibitory activity of CPT derivatives. These results can offer useful references for directing the molecular design of Topo-I inhibitor with improved anticancer activity.
Retrieval of Crystal structures  3D crystal structure of DNA Topo-I protein (PDB: 1T8I) and chemical compounds were retrieved from PDB (www.rcsb.org) and PubChem databases respectively. Cleaning, Optimization & molecular docking of CPT derivatives  3D structure of CPT derivatives were designed and optimized through ChemBioOffice software. Molecular structures of target protein Topo-I and chemical molecules were prepared and docked through Scigress Explorer v7.7 (Fujitsu). Molecular docking was performed to find out the binding affinity or molecular interaction energy (kcal/mol) of docked compounds calculated by using PMF scoring scheme. Lowest energy of docked molecule indicates high binding affinity with the target protein. Binding pocket of docked CPT active derivatives were studied for selection radius 3Å. Multiple linear regression QSAR modeling for anticancer activity targeting Topo-I  Calculation of 2D and 3D molecular chemical descriptors for QSAR modeling by using forward feed multiple linear regression method and drug likeness study (Lipinski et. al., 2001 ) was done through Scigress Explorer v7.7. The model was constructed with 45 compounds in the training set, which was validated by the remaining molecules in the test set. We employed 'leave-one-out' cross validation procedure.
Conclusion
• The docking results of 10 CPT derivatives showed that the active residues of Topo-I binding pocket are hydrophilic and polar in nature.
• There was a significant correlation between binding affinity (docking energy) and the experimental IC 50 .
• Moreover, Asp-533, Arg-364, Gln-421, and Lys-374 are the key residues in the binding pockets responsible for molecular binding with CPT derivatives.
• QSAR model for CPT derivatives was successfully developed to understand the interaction factors governing its activity. Results indicate that the developed QSAR model is robust and have good predictive capability for anticancer activity targeting Topo-I.
• The QSAR results indicate that hydrogen bonds highly contribute to inhibitory activity, followed by hydrophobic and electrostatic factors.
• The results of QSAR were consistent with the molecular docking.
Results
• MLR method was employed to generate a linear relationship that correlates changes in the computed steric and electrostatic potential fields with changes in the corresponding experimental values of the training compounds activity (IC 50 ).
• Docking results showed that all the active CPT derivatives docked on Topo-I with high binding affinity.
• 2D contour maps of CPT derivatives were compared with the crystal structure of Topo-I complex (PDB: 1T8I).
• Docking results of 10 CPT derivatives showed that the important residues of Topo-I active pocket are hydrophilic and polar.
• Asp-533, Arg-364, Gln-421, & Lys-374 are the key residues in the binding pockets responsible for molecular binding with CPT derivatives.
• QSAR results indicate that connectivity index, electron affinity, molecular weight, & ether group count highly contribute to inhibitory activity of CPT derivatives on Topo-I, followed by H-bond, hydrophobic and electrostatic factors.  In the current era, one of the leading disease related causes of death of the human population in the world is cancer and it is predicted to continue to be the same in the coming years (Gibbs JB, 2000) .  Topotecan is presently indicated as a second-line therapy for advanced ovarian cancer and small-cell lung cancer. Irinotecan is approved for use in the treatment of advanced colorectal cancer, both as first-line therapy in combination with 5-FU and as salvage treatment in 5-FU refractory disease, including 9-AC, 9-NC, GI-147211, exatecan mesylate, and karenitecin. A lot of CPT analogs have been synthesized and evaluated, several 3D QSAR studies of CPT were reported from laboratories, but failed in clinical trials (Carrigan SW et al., 1997) .  So far Yoon et al. (2003) have successfully developed the QSAR model for CPT derivatives other then present study targeting serum esterase and designed a new, easily activated SN-38 prodrug for anticancer activity (Yoon KJP et al., 2003) .  In the studied work, we successfully build the predictive multiple linear regression QSAR model for anticancer activity, targeting Topo-I by using CPT and other known anticancer drugs. In order to further understand the inhibition mechanism of CPT derivatives and to guide structural modification in CPT analogs, a QSAR and molecular docking studies of CPT derivatives was performed.
